Primary Vesicoureteral Reflux in Children
儿童原发性膀胱输尿管反流
基本信息
- 批准号:7036386
- 负责人:
- 金额:$ 45.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-30 至 2010-05-31
- 项目状态:已结题
- 来源:
- 关键词:antiinfective agentsbiomaterialschemopreventionchild (0-11)clinical researchclinical trialsconstipationcooperative studydisease /disorder prevention /controlhuman subjecthuman therapy evaluationimplantinjurykidney disorderlongitudinal human studypatient oriented researchpediatric pharmacologypediatricsrelapse /recurrencescarsurinary bladder disorderurinary tract imaging /visualizationurinary tract infectionurinary tract surgeryurination disorder
项目摘要
DESCRIPTION (provided by applicant):
Primary vesicoureteral reflux (VUR) is a common problem, occuring [sic] in 8-50% of children with urinary tract infection (UTI). It has the potential for causing irreparable renal damage, particularly [sic] in younger children. Despite the widespread use of antibiotic prophylaxis in children with VUR, there are no placebo-controlled studies demonstrating its clinical benefit in preventing renal injury. The main aim of our proposed double blind, placebo-controled [sic] study is to test the hypothesis that prolonged antibiotic prophylaxis in children > 2 years old with grade I-IV VUR is unnecessary. Our study, which is a joint effort of 28 Pediatric Nephrologists and 9 Pediatric Urologists from 28 centers affiliated with the North American Pediatrics Renal Transplant Registry (NAPRTCS) and the Midwest Pediatric Nephrology Consortium (MWPNC) will test this hypothesis by recruiting 120 children up to the age of 10 years with newly diagnosed grades I-IV VUR. We propose using antibiotic prophylaxis in all eligible subjects up to the age of 2 years or a minimum of 6 months from the diagnosis of VUR (whichever comes later) and subsequently randomizing them into prophylaxis and placebo groups. Children >2 years old will be randomized directly at study entry into prophylaxis and placebo groups. Followup will include biannual clinc [sic] visits; yearly renal imaging, blood and urine tests, and assessment for dysfunctional voiding (DV) and constipation; and the measurement of glomerular filtration rate by iohexol clearance. By randomization, we will test our first hypothesis that antibiotic prophylaxis after age 2 years does not decrease the frequency of UTI, reduce the risk of renal scarring, or enhance resolution of VUR. By using objecitve [sic] scoring for DV and constipation, we will test our second hypothesis that their presence delays resolution of VUR, and increases the frequency of UTI and renal scarring, irrespective of long-term antibiotic prophylaxis. Patients who fail medical management will be randomized into Delfux or surgical reimplantation groups to test our third hypothesis that the two treatments do not differ in cure rate, recurrence rate of UTI, or risk of renal scarring.
Vesicoureteral reflux, the abnormal flow of urine from the bladder into the kidneys, is common in children and may cause kidney damage and high blood pressure. Current treatment uses daily antibiotics for years, but this may not be necessary and may cause some harm, inlcuding [sic] resistance to antibiotics, requiring children to have expensive and painful radiology tests and surgical procedures, and causing parental anxiety. This study will determine if long-term antibiotics are necessary in children with VUR
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TEJ K MATTOO其他文献
TEJ K MATTOO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TEJ K MATTOO', 18)}}的其他基金
Tacrolimus and Plasmapheresis in Treatment-Resistant FSGS
他克莫司和血浆置换治疗难治性 FSGS
- 批准号:
7176978 - 财政年份:2006
- 资助金额:
$ 45.28万 - 项目类别:
Tacrolimus and Plasmapheresis in Treatment-Resistant FSGS
他克莫司和血浆置换治疗难治性 FSGS
- 批准号:
7295745 - 财政年份:2006
- 资助金额:
$ 45.28万 - 项目类别:
相似国自然基金
碳/碳复合材料膺复体联合自体空肠移植喉气管重建的实验研究
- 批准号:50372003
- 批准年份:2003
- 资助金额:25.0 万元
- 项目类别:面上项目
相似海外基金
POET Study: Clinical Trial of Girls with Reflux
POET 研究:患有反流的女孩的临床试验
- 批准号:
7036443 - 财政年份:2005
- 资助金额:
$ 45.28万 - 项目类别:
Randomized Intervention for Vesico-Ureteral Reflux (RIV*
膀胱输尿管反流的随机干预 (RIV*
- 批准号:
7127268 - 财政年份:2005
- 资助金额:
$ 45.28万 - 项目类别:
Randomized Intervention for Vesico-Ureteral Reflux (RIV*
膀胱输尿管反流的随机干预 (RIV*
- 批准号:
7035584 - 财政年份:2005
- 资助金额:
$ 45.28万 - 项目类别:
POET Study: A Randomized Multi-institutional Clinical T*
POET 研究:随机多机构临床 T*
- 批准号:
7127231 - 财政年份:2005
- 资助金额:
$ 45.28万 - 项目类别:
FUNCTIONAL BIOMATERIALS FOR ANTISENSE DELIVERY TO ISLET
用于向胰岛输送反义酶的功能性生物材料
- 批准号:
6982773 - 财政年份:2003
- 资助金额:
$ 45.28万 - 项目类别:
FUNCTIONAL BIOMATERIALS FOR ANTISENSE DELIVERY TO ISLET
用于向胰岛输送反义酶的功能性生物材料
- 批准号:
6835144 - 财政年份:2003
- 资助金额:
$ 45.28万 - 项目类别:
FUNCTIONAL BIOMATERIALS FOR ANTISENSE DELIVERY TO ISLET
用于向胰岛输送反义酶的功能性生物材料
- 批准号:
6703536 - 财政年份:2003
- 资助金额:
$ 45.28万 - 项目类别:
Topical 'photo-chemoprevention' of oral leukoplakia
口腔白斑的局部“光化学预防”
- 批准号:
6502338 - 财政年份:2001
- 资助金额:
$ 45.28万 - 项目类别:
Topical 'photo-chemoprevention' of oral leukoplakia
口腔白斑的局部“光化学预防”
- 批准号:
6334362 - 财政年份:2001
- 资助金额:
$ 45.28万 - 项目类别: